Plasma matrix composite membrane as well as preparation method and application thereof

By modifying and superimposing the plasma matrix membrane, the problems of insufficient width and thickness of plasma matrix membrane and rapid degradation are solved, and its effect in tissue regeneration and wound healing is improved, and the use time and scenario are extended.

CN119075010APending Publication Date: 2024-12-06HUBEI PRIME SHIELD BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411290691.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The width and thickness of the existing plasma matrix membrane cannot meet clinical needs, the degradation time is short, and it cannot be used for long-term use to promote tissue regeneration and wound healing, low biological activity, and a single use scenario.

Method used

By soaking the plasma matrix membrane in a biological crosslinker solution and modifying it and superimposing and pressing it according to clinical needs, it can improve its width, thickness, toughness and mechanical strength, extend the degradation time, and enhance the growth factor release ability.

Benefits of technology

The prepared plasma matrix composite membrane has higher toughness and mechanical strength, extends the degradation time, can continuously release growth factors, significantly improve tissue regeneration and wound healing capabilities, and widens clinical use scenarios.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119075010A_ABST
    Figure CN119075010A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological materials, in particular to a plasma matrix composite membrane and a preparation method and application thereof. The preparation method comprises the following steps: (1) centrifuging blood to obtain plasma matrix gel, and pressing the plasma matrix gel into a film to obtain a plasma matrix film; and (2) soaking the plasma matrix membrane in a biological cross-linking agent solution for modification to obtain a modified plasma matrix membrane, and overlapping and bonding at least two modified plasma matrix membranes and pressing into a membrane to obtain the plasma matrix composite membrane. According to the preparation method provided by the invention, the size and the thickness of the plasma matrix composite membrane can be flexibly designed according to clinical requirements, and the prepared plasma matrix composite membrane is good in toughness, high in mechanical strength, slow in degradation rate, more in total amount of released growth factors and more durable in growth factor release capability; the hydrogel has excellent capabilities of promoting tissue regeneration and wound healing, and can provide continuous growth factors and barrier protection for tissue regeneration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomaterials, and in particular to a plasma matrix composite membrane and a preparation method and application thereof. Background Art

[0002] Plasma matrix is ​​a biomaterial derived from autologous peripheral blood. Due to its good ability to promote the regeneration of soft and hard tissues, plasma matrix has been widely used in clinical fields such as oral soft and hard tissue defects and the healing of refractory skin wounds in recent years. The significant repair effect of plasma matrix comes from the living cells such as platelets, fibrin scaffolds and growth factors that can promote tissue healing contained in it. Plasma matrix membrane has excellent physical properties and good barrier function, and plays a major role in wound healing and repair. However, the plasma matrix membrane prepared under current technical conditions is limited by the size of the blood collection tube, so the width and thickness sometimes cannot meet the needs of soft and hard tissue defects in the oral cavity, and the total amount of sustained-release growth factors is not high, and the degradation time in the body is short, which cannot meet the needs of long-term wound healing, and the clinical use scenario is relatively single. Summary of the invention

[0003] In order to solve the above technical problems, the present invention provides a plasma matrix composite membrane and a preparation method and application thereof. The preparation method provided by the present invention can flexibly design the size and thickness of the plasma matrix composite membrane according to clinical needs, significantly improve the width and thickness of the plasma matrix composite membrane, and the prepared plasma matrix composite membrane has good toughness, high mechanical strength, slow degradation rate, more total amount of growth factor release and more lasting growth factor release ability, has excellent ability to promote tissue regeneration and wound healing, can provide continuous growth factors and barrier protection for tissue regeneration, and solves the problems of small morphology, low strength, fast degradation, low biological activity, and inability to be used for long-term promotion of tissue regeneration and wound healing of the current plasma matrix membrane.

[0004] In a first aspect, the present invention provides a method for preparing a plasma matrix composite membrane, the preparation method comprising the following steps:

[0005] (1) centrifuging blood to obtain a plasma matrix gel, and pressing the plasma matrix gel into a membrane to obtain a plasma matrix membrane;

[0006] (2) The plasma matrix membrane is immersed in a biocrosslinking agent solution for modification to obtain a modified plasma matrix membrane, and at least two of the modified plasma matrix membranes are stacked, bonded and pressed into a membrane to obtain the plasma matrix composite membrane.

[0007] The preparation method provided by the present invention can flexibly design the size and thickness of the plasma matrix composite membrane according to clinical needs, significantly improving the width and thickness of the plasma matrix composite membrane. The prepared plasma matrix composite membrane has good toughness, high mechanical strength, slow degradation rate, more total amount of growth factor release and longer-lasting growth factor release ability, and has excellent ability to promote tissue regeneration and wound healing. Specifically:

[0008] The preparation method provided by the present invention utilizes a biocrosslinking agent to modify the plasma matrix membrane, and then stacks it to a required area or thickness according to clinical needs, and uses a special instrument to press it, so that the modified plasma matrix membranes are cross-linked to form a whole to obtain a plasma matrix composite membrane, which significantly improves the width and thickness of the plasma matrix membrane. Moreover, since multiple plasma matrix membranes are stacked together, the plasma matrix composite membrane releases a larger total amount of growth factors and has a more sustained growth factor release ability. At the same time, the plasma matrix membrane treated with the biocrosslinking agent can form a dense fibrin network structure inside, making it stronger and more flexible, thereby effectively improving the toughness and mechanical strength of the plasma matrix composite membrane, prolonging the degradation time, and when applied to tissue regeneration and wound healing, it can be retained for a longer time, improving the therapeutic effect, and broadening the clinical use scenarios.

[0009] As a preferred technical solution of the present invention, the biocrosslinking agent includes any one or more of polylysine, genipin, acetic anhydride, diglycidyl ethyl ether and methyl succinimidyl ester.

[0010] The biocrosslinking agent provided by the present invention can modify the plasma matrix membrane, so that the adjacent plasma matrix membrane surfaces stacked together are re-crosslinked to achieve a bonding effect. On the basis of increasing the width and thickness of the plasma matrix membrane, its toughness and mechanical strength are improved, and its barrier function is enhanced, so that the prepared plasma matrix composite membrane has a prolonged degradation time and sustained growth factor release time, and the total amount of sustained growth factor is greater, and the ability to promote bone regeneration is stronger.

[0011] As a preferred technical solution of the present invention, the volume ratio of the biocrosslinking agent solution to blood is 0.01-1:10, for example, 0.01:10, 0.05:10, 0.1:10, 0.5:10, 1:10, etc.

[0012] As a preferred technical solution of the present invention, the concentration of the biocrosslinking agent solution is 0.01-0.2 g / mL, such as 0.01 g / mL, 0.05 g / mL, 0.1 g / mL, 0.15 g / mL, 0.2 g / mL, etc.

[0013] As a preferred technical solution of the present invention, the solvent in the biocrosslinking agent solution is a phosphate buffer solution.

[0014] In step (1) of the present invention, blood is placed in a solid plasma matrix blood collection tube, wherein the amount of blood sample in each blood collection tube is 8-10 mL, and the blood is processed using a centrifugal device before coagulation, preferably a horizontal centrifugation method, to obtain an upper layer of pale yellow gel plasma matrix, a middle brown-yellow layer and a lower layer of red blood cells after centrifugation, and the plasma matrix gel is taken out of the blood collection tube using special tweezers, and then pressed into a film using a special instrument to obtain a plasma matrix membrane.

[0015] As a preferred technical solution of the present invention, the centrifugal acceleration of the centrifugation in step (1) is 60-1000g, for example, 60g, 100g, 200g, 500g, 800g, 1000g, etc.

[0016] As a preferred technical solution of the present invention, the centrifugation time in step (1) is 2-10 min, for example, 2 min, 4 min, 6 min, 8 min, 10 min, etc.

[0017] When the centrifugal acceleration and time of the centrifugation in step (1) are within the above range, the plasma matrix in the blood can be separated more fully.

[0018] As a preferred technical solution of the present invention, the pressure during pressing into film in step (1) is 1-10N, such as 1N, 2N, 4N, 6N, 8N, 10N, etc.

[0019] As a preferred technical solution of the present invention, the pressing time for pressing into a film in step (1) is 0.5-2 min, for example, 0.5 min, 1 min, 1.5 min, 2 min, etc.

[0020] When the pressure and time during the pressing into the membrane in step (1) are within the above range, a more complete and uniform plasma matrix membrane can be obtained.

[0021] As a preferred technical solution of the present invention, the temperature during the modification in step (2) is 37-60°C, for example, 37°C, 40°C, 45°C, 50°C, 55°C, 60°C, etc.

[0022] As a preferred technical solution of the present invention, the modification time in step (2) should be no less than 10 min, preferably 10-60 min, for example 10 min, 20 min, 30 min, 40 min, 50 min, 60 min, etc.

[0023] When the temperature and time of the modification in step (2) are within the above range, the plasma matrix membrane can be more fully cross-linked and modified.

[0024] As a preferred technical solution of the present invention, the pressure during pressing into film in step (2) is 0.1-10N, such as 0.1N, 1N, 2N, 5N, 10N, etc.

[0025] As a preferred technical solution of the present invention, the pressing time for pressing into film in step (2) is ≥ 1 min.

[0026] When the pressure and time during the pressing into the membrane in step (2) are within the above range, a more complete and uniform plasma matrix composite membrane can be obtained.

[0027] In a second aspect, the present invention provides a plasma matrix composite membrane prepared by the preparation method described in the first aspect.

[0028] The plasma matrix composite membrane provided by the present invention has good toughness, high mechanical strength, slow degradation rate, a larger total amount of growth factor release and a more sustained growth factor release ability, has excellent ability to promote tissue regeneration and wound healing, and can be used in oral soft and hard tissue defects to promote regeneration.

[0029] In a third aspect, the present invention provides the use of the plasma matrix composite membrane described in the second aspect in materials for promoting tissue regeneration and wound healing.

[0030] The technical solution provided by the embodiment of the present invention has the following advantages compared with the prior art:

[0031] The preparation method provided by the present invention can flexibly design the size and thickness of the plasma matrix composite membrane according to clinical needs, significantly improving the width and thickness of the plasma matrix membrane. The prepared plasma matrix composite membrane has good toughness, high mechanical strength, slow degradation rate, a larger total amount of growth factor release and a more sustained growth factor release ability, has excellent ability to promote tissue regeneration and wound healing, and can provide continuous growth factors and barrier protection for tissue regeneration, solving the problems of the current plasma matrix membrane having small morphology, low strength, fast degradation, low biological activity, and inability to be used for long-term promotion of tissue regeneration and wound healing. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the invention and, together with the description, serve to explain the principles of the invention.

[0033] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0034] Figure 1This is a flow chart of the preparation of the plasma matrix composite membrane described in Example 1 of the present invention;

[0035] Figure 2 This is a SEM image of the plasma matrix composite membrane prepared in Example 1 of the present invention;

[0036] Figure 3 This is a SEM image of the plasma matrix composite membrane prepared in Example 2 of the present invention;

[0037] Figure 4 This is a SEM image of the plasma matrix membrane prepared in Comparative Example 1 of the present invention;

[0038] Figure 5 This is a comparison diagram of the maximum stress of the plasma matrix membrane products prepared in Examples 1-2 of the present invention and Comparative Example 1;

[0039] Figure 6 This is a comparison diagram of the maximum strain of the plasma matrix membrane products prepared in Examples 1-2 of the present invention and Comparative Example 1;

[0040] Figure 7 It is a degradation behavior curve diagram of the plasma matrix membrane products prepared in Examples 1-2 of the present invention and Comparative Example 1;

[0041] Figure 8 This is a diagram showing the barrier effects of the plasma matrix membrane products prepared in Examples 1-2 and Comparative Example 1 of the present invention. DETAILED DESCRIPTION

[0042] In order to more clearly understand the above-mentioned objectives, features and advantages of the present invention, the scheme of the present invention will be further described below. It should be noted that the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

[0043] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein; it is obvious that the embodiments in the specification are only part of the embodiments of the present invention, rather than all of the embodiments.

[0044] Example 1

[0045] This embodiment provides a plasma matrix composite membrane and a preparation method thereof. The schematic flow diagram of the preparation method is as follows: Figure 1 As shown, the specific steps include:

[0046] (1) Collect 10 mL of whole blood sample in a glass plasma matrix blood collection tube, quickly place it in a horizontal centrifuge and centrifuge it at a centrifugal acceleration of 700 g for 8 minutes to obtain an upper solid plasma matrix clot, use scissors to bluntly separate the lower red blood cell layer from the obtained upper solid plasma matrix clot, and then use a special film pressing device box (Pulime Shield) to press it into a film shape at a pressure of 1 N for 2 minutes to obtain a plasma matrix membrane;

[0047] (2) immersing the plasma matrix membrane in a poly-lysine phosphate buffer for 10 minutes for modification, the temperature is 37° C., the volume ratio of the biocrosslinking agent solution to the blood is 0.05:10, to obtain a modified plasma matrix membrane, and after stacking two layers of the modified plasma matrix membrane, using a dedicated instrument to press and bond them, the pressure is 1N, and the pressing time is 2 minutes, to obtain the plasma matrix composite membrane;

[0048] The whole blood sample was collected from the cubital fossa of the volunteer. The glass plasma matrix blood collection tube was purchased from Primedun. The concentration of the biological cross-linked phosphate buffer was 0.1 g / mL. The platelet content in the whole blood sample was 100×10 9 -300×10 9 / Lift.

[0049] Example 2

[0050] This embodiment provides a plasma matrix composite membrane and a preparation method thereof. The preparation method is the same as that of Example 1, and the difference from Example 1 is that in step (2) of this embodiment, three layers of modified plasma matrix membranes are stacked and pressed to obtain the plasma matrix composite membrane.

[0051] Example 3

[0052] This embodiment provides a plasma matrix composite membrane and a preparation method thereof, the preparation method comprising the following steps:

[0053] (1) Collect 10 mL of whole blood sample in a glass plasma matrix blood collection tube, quickly place it in a horizontal centrifuge and centrifuge it at a centrifugal acceleration of 600 g for 2 min to obtain an upper solid plasma matrix clot, use scissors to bluntly separate the lower red blood cell layer from the obtained upper solid plasma matrix clot, and then use a special film pressing device box (Pulime Shield) to press it into a film shape at a pressure of 1 N for 2 min to obtain a plasma matrix membrane;

[0054] (2) immersing the plasma matrix membrane in acetic anhydride phosphate buffer for 10 minutes for modification, the temperature is 45° C., the volume ratio of the biocrosslinking agent solution to the blood is 0.05:10, to obtain a modified plasma matrix membrane, and after stacking 3 layers of the modified plasma matrix membrane, using a dedicated instrument to press and bond them, the pressure is 1N, and the pressing time is 2 minutes, to obtain the plasma matrix composite membrane;

[0055] The whole blood sample was collected from the cubital fossa of the volunteer. The glass plasma matrix blood collection tube was purchased from Primedun. The concentration of the biological cross-linked phosphate buffer was 0.1 g / mL. The platelet content in the whole blood sample was 100×10 9 -300×10 9 / Lift.

[0056] Example 4

[0057] This embodiment provides a plasma matrix composite membrane and a preparation method thereof, the preparation method comprising the following steps:

[0058] (1) Collect 10 mL of whole blood sample in a glass plasma matrix blood collection tube, quickly place it in a horizontal centrifuge and centrifuge it at a centrifugal acceleration of 500 g for 5 minutes to obtain an upper solid plasma matrix clot, use scissors to bluntly separate the lower red blood cell layer from the obtained upper solid plasma matrix clot, and then use a special film pressing device box (Pulime Shield) to press it into a film shape at a pressure of 1 N for 2 minutes to obtain a plasma matrix membrane;

[0059] (2) immersing the plasma matrix membrane in a phosphate buffer solution of diglycidyl ether for 10 minutes for modification, the temperature is 60° C., the volume ratio of the biocrosslinking agent solution to the blood is 0.05:10, and a modified plasma matrix membrane is obtained. After 5 layers of the modified plasma matrix membrane are stacked, they are pressed and bonded using a dedicated instrument at a pressure of 5N and a pressing time of 1 minute to obtain the plasma matrix composite membrane;

[0060] The whole blood sample was collected from the cubital fossa of the volunteer. The glass plasma matrix blood collection tube was purchased from Primedun. The concentration of the biological cross-linked phosphate buffer was 0.1 g / mL. The platelet content in the whole blood sample was 100×10 9 -300×10 9 / Lift.

[0061] Example 5

[0062] This embodiment provides a plasma matrix composite membrane and a preparation method thereof. The preparation method is the same as that of Example 1. The difference from the embodiment is that in this embodiment, the centrifugal acceleration is 60g and the centrifugal time is 10min.

[0063] Comparative Example 1

[0064] This comparative example provides a plasma matrix composite membrane and a preparation method thereof. The preparation method is the same as that of Example 1. The difference from the example is that only step (1) is performed in this comparative example, that is, only an ordinary plasma matrix membrane is obtained.

[0065] Performance Testing

[0066] 1. The plasma matrix membrane products prepared in the examples and comparative examples were subjected to SEM testing.

[0067] The SEM image of the plasma matrix composite membrane prepared in Example 1 is as follows: Figure 2 As shown, the SEM image of the plasma matrix composite membrane prepared in Example 2 is as follows Figure 3 As shown, the SEM image of the plasma matrix membrane prepared in Comparative Example 1 is as follows Figure 4 shown.

[0068] Depend on Figure 2-4 It can be found that the plasma matrix composite membrane prepared after superposition has a denser internal fibrin network structure and higher strength.

[0069] 2. The plasma matrix membrane products prepared in the examples and comparative examples were subjected to tensile tests. The maximum stress diagrams of the plasma matrix membrane products prepared in Examples 1-2 and Comparative Example 1 are shown in FIG. Figure 5 As shown in the figure, the maximum strain diagram is Figure 6 shown.

[0070] Depend on Figure 5-6 It can be found that the tensile properties of the plasma matrix composite membrane prepared after superposition are better.

[0071] 3. The degradation performance of the plasma matrix membrane products prepared in the examples and comparative examples was tested.

[0072] The plasma matrix composite membranes prepared in Examples 1-2 and the ordinary plasma matrix membranes prepared in Comparative Example 1 were placed in 10% serum DMEM for degradation test. The quality of the composite membranes was measured at 1d, 3d, 5d, 7d, 14d, 21d, and 28d to observe the degradation. The results are as follows: Figure 7 shown.

[0073] Depend on Figure 7It can be found that the plasma matrix composite membrane prepared by superposition of the present invention has a slower degradation rate and a significantly longer degradation time than ordinary plasma matrix membranes, and can release growth factors that promote tissue regeneration for a long time. This shows that when the plasma matrix composite membrane of the present invention is used to guide bone regeneration surgery, the implanted plasma matrix composite membrane can support the defect position for a longer time and play a better role as a soft tissue barrier; the plasma matrix composite membrane of the present invention is easy to prepare and can be easily obtained from the patient himself, so it is usually not necessary to obtain it from other individuals, avoiding the risk of immune rejection.

[0074] 4. Barrier effects of plasma matrix membrane products prepared in Examples and Comparative Examples.

[0075] The plasma matrix composite membranes prepared in Examples 1-2 and the ordinary plasma matrix membranes prepared in Comparative Example 1 were inoculated with HGF cells, and the number of cells on the upper and lower surfaces of the membranes, as well as the number of cells that penetrated the plasma matrix membranes and reached the glass slide below the plasma matrix membranes were evaluated three days later. The results are shown in FIG. Figure 8 shown.

[0076] Depend on Figure 8 It can be found that the plasma matrix composite membrane prepared by stacking of the present invention has fewer cells passing through it and can play a better role as a soft tissue barrier.

[0077] The present invention selected whole blood samples from 15 volunteers to carry out the treatments of Examples 1-3, and the obtained plasma matrix composite membranes all had the characteristics of denser fibrin structure, higher strength, slower degradation, and better osteogenesis effect.

[0078] It should be noted that, in this article, relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, the elements defined by the sentence "comprise a ..." do not exclude the existence of other identical elements in the process, method, article or device including the elements.

[0079] The above description is only a specific embodiment of the present invention, so that those skilled in the art can understand or implement the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments described herein, but should conform to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A method for preparing a plasma matrix composite membrane, It is characterized in that The preparation method comprises the following steps: (1) centrifuging blood to obtain a plasma matrix gel, and pressing the plasma matrix gel into a membrane to obtain a plasma matrix membrane; (2) The plasma matrix membrane is immersed in a biocrosslinking agent solution for modification to obtain a modified plasma matrix membrane, and at least two of the modified plasma matrix membranes are stacked, bonded and pressed into a membrane to obtain the plasma matrix composite membrane.

2. The preparation method according to claim 1, It is characterized in that The biological cross-linking agent includes any one or more of poly-lysine, genipin, acetic anhydride, diglycidyl ethyl ether and methyl succinimidyl.

3. The preparation method according to claim 1 or 2, It is characterized in that The volume ratio of the biocrosslinking agent solution to blood is 0.01-1:

10.

4. The preparation method according to any one of claims 1 to 3, It is characterized in that The concentration of the biocrosslinking agent solution is 0.01-0.2 g / mL; And / or, the solvent in the biocrosslinking agent solution is a phosphate buffer solution.

5. The preparation method according to any one of claims 1 to 4, It is characterized in that The centrifugal acceleration of the centrifugation in step (1) is 60-1000g; And / or, the centrifugation time in step (1) is 2-10 min.

6. The preparation method according to any one of claims 1 to 5, It is characterized in that The pressure during the pressing into the film in step (1) is 1-10N; And / or, the pressing time during the pressing into film in step (1) is 0.5-2 min.

7. The preparation method according to any one of claims 1 to 6, It is characterized in that The temperature during the modification in step (2) is 37-60° C. And / or, the modification time in step (2) is 10-60 min.

8. The preparation method according to any one of claims 1 to 7, It is characterized in that The pressure during the pressing into the film in step (2) is 0.1-10N; And / or, the pressing time for pressing into film in step (2) is ≥ 1 min.

9. The plasma matrix composite membrane prepared by the preparation method according to any one of claims 1 to 8.

10. Use of the plasma matrix composite membrane according to claim 9 in materials for promoting tissue regeneration and wound healing.